Metrics as of 10/13/2026, 06:41 PM (Berlin time), refresh in progress.
Tecan Group Stock
Tecan Group AG
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- Switzerland
- CEO
- Monica Manotas
- Employees
- 3,000
- Market cap
- CHF3 B
- IPO
- 10/04/1995
Tecan Group AG is headquartered in Männedorf, Switzerland, and operates within the Healthcare sector. Established in 1980, the company specializes in providing cutting-edge laboratory instruments and holistic solutions. Its diverse client base includes pharmaceutical and biotechnology corporations, university research…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Tecan Group stock: price history
1D
+1.0%
1W
-3.2%
1M
+20.3%
6M
+69.9%
YTD
+86.3%
1Y
+67.1%
2Y
-9.6%
5Y
-53.1%
10Y
+38.8%
Next earnings date
Next earnings date
16/03/2027 (in 150 days)
Volatility around earnings
~56% stronger price swings than usual
Tecan Group stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
2 more assignments (Enabler/Second row) Pro-only.
Tecan Group AG is a specialized provider of laboratory instruments and comprehensive solutions for life sciences, diagnostics, and research. The business model is divided into a Life Sciences business and a Partnering business. The portfolio comprises automated liquid handling systems, microplate readers, consumables, reagents for NGS, and specialized software solutions such as Resolvex. This allows the company to serve a broad customer base ranging from pharma and biotechnology to research institutions and laboratories. In addition to selling its own instrument portfolio, Tecan also manufactures critical components such as precision pumps and robotic arms for other laboratory instrument manufacturers. The business model combines hardware sales with recurring revenues generated through consumables and software.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Low
Ask the agents about Tecan Group
Tecan Group stock metrics
P/E
-26.14
P/B
2.65
EV/EBITDA
31.81
RETURN ON EQUITY
1.1%
NET MARGIN
2.9%
DEBT/EQUITY
0.19
DIVIDEND YIELD
1.3%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.6%
FLOAT SHARES
12,479,322
AVG. DAILY VOLUME (30D)
74,906
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Tecan Group stock
What does Tecan Group do?
Tecan Group AG is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in Switzerland.
The CEO is Monica Manotas, the company employs around 3,000 people.
The IPO was on 10/04/1995; the stock trades on SIX under the ticker TECN.SW.
When does Tecan Group report next?
The next earnings date is 16/03/2027.
Around past earnings, price swings were roughly 56% stronger than usual.
Does Tecan Group pay a dividend?
Yes. The last dividend was CHF 3.00 per share, ex-date 17/04/2026, paid on 21/04/2026.
The dividend yield is 1.3% (as of 30/06/2026).
Which stocks are comparable to Tecan Group?
Comparable stocks include SKAN Group, Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Sartorius, Solventum and Baxter International.
How can I get Tecan Group stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tecan Group against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.